2,6-Difluorobenzyl chloride

This key intermediate introduces the characteristic difluorobenzyl moiety, essential for Rufinamide’s therapeutic action in treating Lennox-Gastaut syndrome seizures. 2,6-Difluorobenzyl chloride is a crucial starting material for synthesizing Rufinamide, an anticonvulsant drug, serving as the source for the difluorobenzyl group, typically converted to 2,6-difluorobenzyl azide which then undergoes cycloaddition with an alkyne (like propiolic acid derivatives) to form the 1,2,3-triazole ring core of Rufinamide through Click chemistry.